Building capacity for a CHC response to Ontario's Opioid Crisis
|
|
- Janis Burke
- 5 years ago
- Views:
Transcription
1 Building capacity for a CHC response to Ontario's Opioid Crisis Rob Boyd Oasis Program Director Luc Cormier, RN, MScN Community Health Nurse Sandy Hill Community Health
2 CFPC Conflict of Interest Presenter Disclosure Presenters: Rob Boyd & Luc Cormier Relationships to commercial interests: Grants/Research Support: None Speakers Bureau/Honoraria: None Consulting Fees: None Other: None
3 Learning objectives 1) Learn basic pharmacological and physiological properties of methadone and buprenorphinenaloxone in order to understand their use in managing opioid use disorder; 2) Gain a better understanding of the various models of care for opioid replacement treatment currently being used in a CHC; 3) Explore the benefits and challenges of integrating addiction medicine within existing primary care settings such as CHCs.
4 What does your organization need to consider increasing your role in treating Opioid Use Disorder?
5 Oasis Program Oasis provides harm reduction based primary health care and social services to people at risk of HIV/AIDS and hepatitis C who experience barriers to accessing care due to overwhelming addiction to street drugs and cooccuring mental illness. Image: Art piece made by peers
6 Primary health care services The Drop-In Housing First Program Case Management Opioid Substitution Therapy Health Promotion Needle and Crack Pipe Distribution Program Support Groups Addictions and Mental Health Counseling Community Development
7 Is this problem common worldwide?
8 Opioid Crisis: Scope of the Problem Narcotics Monitoring System: April to Sept million dispensing events 5.1 million different patients different prescribers Opioid Agonist Treatment 2014/2015 MMT / Suboxone /
9 Substance use disorder in Canada Approximately 21.6% of Canadians aged 15 and over will meet the criteria for a substance use disorder in their lifetime. Alcohol 18.6% Cannabis 6.8% Others 4%
10 Opioid Use Disorder in Ontario
11 Opioid related deaths, by drug 1 in 170 deaths related to opioid use 1 in 8 among young adults aged 25-34
12 Opioid Overdoses Number of Opioid toxicity Deaths by Drug in Ontario Office of the Chief Coroner and Ontario Forensic Pathology Service Year Codeine Fentanyl Heroin Hydromorph Methadone Morphine Oxycodone
13 Case Study Case Scenario develop a treatment plan based on your current knowledge (issues/barriers/facilitators) Small groups discussion Details of case study to come
14 Goals of SUD treatment Treatment retention Reducing harm caused by substances Reduction in severity and frequency of substance use Management of concurrent psychiatric and medical conditions
15 Goals of SUD treatment Improving all areas of life affected by SUD (employment, interpersonal relationships, interface with the law/criminal justice system) Improving all levels of adaptive functioning Preventing relapse to substance use
16 Principles of treatment Treatment must be culturally-sensitive taking into consideration special populations including and pregnant women, ethnic minorities, individuals who identify as LGBTQ Recovery is conceptualized as a process rather than an event and is individualized for and defined by each client Treatment should include pharmacology, mutually agreed upon treatment goals, education, and interdisciplinary care
17 Continuum of Substance Use Treatment Concurrent disorders Chronic Non Use Abstinence Managed Use Problematic Use Complex Addiction Annual Screening of substance use and mental health Screen, brief intervene, treat and refer, biopsychosocial, Addiction medicine Low threshold medical, pragmatic support, SIS
18 Pharmacotherapy for opioid use disorder Opioid agonists Opioid antagonists Symptomatic treatment of withdrawals Opioid agonists are generally use for moderate to severe presentations of OUD. Often referred to as opioid substitution therapy (OST) or opioid agonist treatment (OAT) Buprenorphine-naloxone and methadone (MTD: requires a special license). Opioid antagonists block the opioid receptors and their effect. Symptomatic treatment with clonidine, acetaminophen, ibuprofen, dimenhydrinate, loperamide, trazodone.
19 Differences between opioid agonists and opioid antagonists Opioid agonists Suppress craving and withdrawal symptoms, and block the acute effects of other opioids Full or partial opioid agonist Opioid antagonists Block effects of other opioids from current or future use Used in overdose situations (naloxone) or as maintenance (naltrexone)
20 Pharmacology of Methadone Methadone (full opioid agonist) Long-acting Binds to and occupies mu-opioid receptors Prevents withdrawal symptoms and reduces craving for opioids Reduces euphoric effects of subsequent opioid use
21 Pharmacology of Methadone Benefits of treatment Increases retention in care Reduces illicit opioid use Associated with reduced spread of HIV infection Reduced criminal behaviour Reduces overall mortality rate Challenges Higher risk of substance misuse and overdose Requires special exemption for Rx Stigma associated with methadone
22 Pharmacology of buprenorphine-naloxone Buprenorphine- naloxone or Suboxone (partial opioid agonist) Ceiling effect due to partial activity (less likely to cause overdose) Binds very tightly to receptors, displaces other opioids (may precipitate withdrawal) Co-formulation with naloxone (opioid antagonist) taken sublingually low bioavailability of naloxone via this route
23 Pharmacology of buprenorphine-naloxone Benefits of treatment Increases retention in care Reduces illicit opioid use (more than methadone) Significantly less risk for lethal overdose (6x lower risk profile) Can be prescribed by primary care physicians Challenges Must be in moderate to severe withdrawal
24 What s the difference between opioid agonist treatment and using drugs? Opportunity for stabilization Ability to focus on other aspects of their life Lessens severity of problematic behaviours associated with OUD
25 Models of care for OST Fee-for-service Bare bones Rapid Access Clinic
26 Fee-for-service Model Billing through OHIP (visits and urine drug screens) Requires health card 330 physicians for patients ~154 patients per physician 72% fewer than 300 patients Very little primary care or psychosocial supports 50% MMT patients are with high volume practices
27 Remuneration through hourly salary Ideal for clients who don t have health cards Low threshold (carries, UDS) Bare Bones Model
28 Bup-nx/Suboxone only Does not require exemption Can be effectively managed in primary care practice Still need competency to prescribe Still need to address psychosocial issues
29 Rapid Access Clinic Model Interested individuals with opioid- or alcohol-related ED visits are referred to RAAM clinic and seen within 7 days Stabilization & transfer to primary care for ongoing management ED-initiated treatment is more effective than conventional approaches
30 Potential Models Primary Care Providers at CHCs begin prescribing suboxone or methadone. CHCs invite FFS OAT prescribers on site and offer integrated primary care and psychosocial support CHCs create formal agreements with stand alone FFS practices to provide primary care and psychosocial support.
31 OAT is best prescribed within an integrated primary care clinic with access to psychosocial supports What would need to happen for your agency to expand services to include Opioid Agonist Therapy in the next 6 months?
32 What information would be helpful to you in considering the possibility of expanding services to include OMT? Knowledge of scope of the problem in my community Access to training for PCPs New resources to operate Understanding on how funding models work/others currently work
33 Questions? Comments? Rob Boyd Director Oasis Program Sandy Hill CHC Luc Cormier Community Health Nurse Sandy Hill CHC
Buprenorphine as a Treatment Option for Opioid Use Disorder
Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital
More informationMedication-Assisted Treatment. What Is It and Why Do We Use It?
Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite
More informationTreatment Alternatives for Substance Use Disorders
Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict
More informationSubstitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
More informationMedical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center
Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers
More informationYouth, Opioid Use and Treatment Options. CPSO MMT Providers Conference Dr. Sharon Cirone MD FCFPC November 2016
Youth, Opioid Use and Treatment Options CPSO MMT Providers Conference Dr. Sharon Cirone MD FCFPC November 2016 Disclosures No propriety involvement in pharmaceutical companies Assessor, CPSO Methadone
More informationBuprenorphine pharmacology
Buprenorphine pharmacology Victorian Opioid Management ECHO Department of Addiction Medicine St Vincent s Hospital Melbourne 2018 Page 1 Opioids full, partial, antagonist Full Agonists - bind completely
More informationMedication Assisted Treatment for Opioid Use Disorders and Veteran Populations
Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations Kamala Greene Genece, Ph.D. VP, Clinical Director Phoenix Houses of New York Benjamin R. Nordstrom, M.D., Ph.D. President
More informationMedication Assisted Treatment. Nicole Gastala, MD
Medication Assisted Treatment Nicole Gastala, MD Objectives Training Goals: To enhance the understanding of the participants in use of medication assisted therapy To increase the knowledge of participants
More informationPharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco
Pharmacotherapy for opioid addiction Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Disclosure slide No commercial conflicts to disclose. Gaps in current treatment of opioid
More information(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)
Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5
More informationWhat Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016
What Science Says about Opioid Use Disorder and Its Treatment Perilou Goddard, Ph.D. Department of Psychological Science Northern Kentucky University Examples of Opioids Agonists (activate opioid receptors)
More informationMedication for Addiction Treatment (MAT)
SBIRT Training Screening, Brief Intervention & Referral to Treatment Medication for Addiction Treatment (MAT) The Faith & Spirituality Integrated SBIRT Network Navigating the Training Welcome! These health
More informationONTARIO S STRATEGY TO PREVENT OPIOID ADDICTION AND OVERDOSE. Dr. David Williams Chief Medical Officer of Health
ONTARIO S STRATEGY TO PREVENT OPIOID ADDICTION AND OVERDOSE Dr. David Williams Chief Medical Officer of Health National opioid-related mortality data, 2016 (Health Canada) Provincial Overdose Coordinator
More informationOpiate Dependency bka Opioid Addiction
Opiate Dependency bka Opioid Addiction GP CME Dunedin July 2012 Doug Sellman Professor of Psychiatry and Addiction Medicine Director, National Addiction Centre University of Otago, Christchurch What this
More informationOAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM
OAT Transitions - focus on microdosing Mark McLean MD MSc FRCPC CISAM DABAM Disclosures No pharmaceutical industry or other financial conflicts of interest Study Physician for research funded by Canadian
More informationNALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018
NALTREXONE DAVID CRABTREE, MD, MPH TREATMENT OF OPIOID USE DISORDER (OUD) Majority of people who develop OUD are not receiving treatment Only a small fraction of patients are offered treatment with medications
More informationShawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine
[Patient-focused, evidence-based addiction treatment] Shawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine BrightView Health All Rights Reserved www.brightviewhealth.com
More informationMedication Assisted Treatment
Meeting the Needs of Your Clients: Building Competencies in Mental Health and Addiction Services Medication Assisted Treatment November 5, 2018 In partnership with: House Keeping Because this is a webinar,
More informationMedications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC
Medications for Opioid Use Disorder Charles Brackett, MD, MPH General Internal Medicine, DHMC Opioid Related Deaths are on the Rise in the US National Vital Statistics System Mortality File Deaths are
More informationMEDICALLY ASSISTED TREATMENT IN PROBLEMATIC OPIOID Punta Cana 2018
MEDICALLY ASSISTED TREATMENT IN PROBLEMATIC OPIOID USE @joelbordman Punta Cana 2018 Copyright 2017 by Sea Courses Inc All rights reserved. No part of this document may be reproduced, copied, stored, or
More informationLONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE
LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE DR. SHILPA ADARKAR ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY & DRUG DEADDICTION CENTRE OF EXCELLENCE SETH GSMC & KEMH LONG TERM OPTIONS FULL AGONIST PARTIAL
More informationThe available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines
The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines Background, Objectives and Methods Systematic reviews (SRs) published by Cochrane Drugs
More informationNational Opioid Treatment Guideline Dr. Ronald Lim
National Opioid Treatment Guideline Dr. Ronald Lim (MD, CCFP, DFASAM, ABAM(D), FISAM, CCSAM, MRO) Clinical Assistant Professor, Department of Psychiatry and Family Practice Cumming School of Medicine University
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationOpioid Use Disorders &Medication Treatment
Agency medical director comments Opioid Use Disorders &Medication Treatment Charissa Fotinos, MD, MSc Deputy Chief Medical Officer Washington State Health Care Authority Learning Objectives: 1) Review
More informationClinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder
Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare
More informationAddiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer
Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South
More informationClinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary
More informationGOALS AND OBJECTIVES
SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More informationAgenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model
Agenda 1 Opioid Addiction in the United States 2 Evidence-based treatments for OUD OUD Treatment: Best Practices 4 Groups: Our Model 2 Groups is a national network of clinics providing affordable, evidencebased
More informationOpioid Use in Youth. Amy Yule M.D. March 2,
Opioid Use in Youth Amy Yule M.D. March 2, 2018 An opioid is a substance that acts on opioid receptors Beta-endorphin Endogenous opioids Dynorphin Opiates Natural products of the poppy plant Morphine Heroin
More informationFaculty/Presenter Disclosure
Provincial Guidelines for the Clinical Management of Opioid Use Disorder Leslie Lappalainen MD Family and Addiction Medicine Medical Lead for Addiction Medicine, Interior Health, Mental Health and Substance
More informationTREATING OPIOID ADDICTION IN HOMELESS POPULATIONS
TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS Challenges and Opportunities Providing Medication Assisted Treatment (Buprenorphine) August 18, 2016 SPEAKERS TODAY Nilesh Kalyanaraman, MD, Chief Health
More informationUSE OF BUPRENORPHINE FOR CHRONIC PAIN
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences USE OF BUPRENORPHINE FOR CHRONIC PAIN MARK SULLIVAN, MD, PHD PSYCHIATRY AND BEHAVIORAL SCIENCES ANESTHESIOLOGY AND
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Methadone and buprenorphine for the management of opioid dependence
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Appraisal Methadone and buprenorphine for the management of opioid dependence Comments received from Consultees and Commentators on the draft scope
More informationOpioid Dependence and Buprenorphine Management
Opioid Dependence and Buprenorphine Management Kevin Kapila, MD Fenway Health Medical Director of Behavioral Health Instructor in Medicine Harvard Medical School Learning Objectives Understand the rationale
More informationThe Opioid-Exposed Woman
The Opioid-Exposed Woman Management Considerations for Labor and Delivery Jane Sublette, MS, RN, CNM, WHNP-BC Fairview Ridges Hospital Objectives Describe opioid-associated risks to the mother and fetus
More informationLinking Opioid Treatment in Primary Care. Roxanne Lewin M.D.
Roxanne Lewin M.D. The Facts Fewer than 10 percent of individuals with an alcohol use disorder and only about 20 percent of individuals with an opioid use disorder receive specialty treatment. Many individuals
More informationHospitals Role in Addressing the Opioid Crisis
Hospitals Role in Addressing the Opioid Crisis Webinar 5: Buprenorphine in the Emergency Department November 14, 2017 Agenda Hospital Based Buprenorphine Initiatives Yngvild Olsen, M.D., Medical Consultant,
More informationAn overview of Medication Assisted Treatment (MAT) and acute pain management on MAT
An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT Goals of Discussion Recognize opioid use disorder (OUD) Discuss the pharmacology of medication assisted treatments (MAT)
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationResponding to the Opioid Epidemic
Responding to the Opioid Epidemic Jessica Gray, MD Addiction Medicine Fellow Boston Medical Center ROME New England August 17, 2017 Disclosures for Jessica Gray, MD No conflicts Learning Objectives Describe
More informationOpioid Review and MAT Clinic CDC Guidelines
1 Opioid Review and MAT Clinic CDC Guidelines January 10, 2018 Housekeeping Use chat feature to inform everyone who s at your clinic Click chat on Zoom option bar Chat Everyone the names of those who are
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationManagement of Opioid Use Disorder in Primary Care
1 Northwest ATTC presents Management of Opioid Use Disorder in Primary Care Joseph O. Merrill, MD, MPH University of Washington Associate Professor of Medicine 4/26/2018 Today s Presenter 2 Joseph Merrill,
More informationIntNSA Webinar Series
BUPRENORPHINE CLINIC: A MULTIDISCIPLINARY MODEL FOR OPIOID MAINTENANCE THERAPY Stephen Strobbe, PhD, RN, NP, PMHCNS-BC, CARN-AP Monday, June 4, 2012 IntNSA Webinar Series Funding for this webinar was made
More informationOpioid Use Disorder Treatment Initiation in Diverse Settings
Opioid Use Disorder Treatment Initiation in Diverse Settings Sarah Wakeman, MD, FASAM Medical Director, Mass General Substance Use Disorder Initiative Assistant Professor, Harvard Medical School Disclosures
More informationSW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass
SW OREGON OPIOID SUMMIT Medication Assisted Recovery for Opioid Use Disorder Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass Opioid Agonists Mu (μ) receptors stimulated by opioids causing full
More informationMethadone Maintenance 101
Methadone Maintenance 101 OTP/DAILY DOSING CLINICS - ANDREW PUTNEY MD Conflicts of Interest - Employed by Acadia HealthCare 1 Why Methadone? At adequate doses methadone decreases opioid withdrawal symptoms
More informationThe Opioid Overdose Crisis: Role of the TB Physician
The Opioid Overdose Crisis: Role of the TB Physician February 22, 2019 Dr. Patricia Daly Chief Medical Health Officer Vancouver Coastal Health Source: Health Canada BC Overdose Deaths 1992 2018 BC Overdose
More informationOpioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine
Natural derivatives of opium poppy - Opium - Morphine - Codeine Opioid Agonists Semi synthetics: Derived from chemicals in opium -Diacetylmorphine Heroin - Hydromorphone Synthetics - Oxycodone Propoxyphene
More informationFY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine
FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine
More informationConfronting the Opioid Epidemic: Suboxone in Primary Care
Confronting the Opioid Epidemic: Suboxone in Primary Care Kami Harless, MD 1 The Opioid Epidemic 2 The Opioid Epidemic 3 Washington Epidemic 4 King County Epidemic 5 King County Epidemic 6 Outline Opioid
More informationThe Opioid Crisis: What Can Physicians Do About It?
The Opioid Crisis: What Can Physicians Do About It? Richard S. Schottenfeld, M.D. Professor and Chair, Department of Psychiatry and Behavioral Sciences 2018 Louis J. Kolodner Memorial Lecture Disclosures
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) For Apple Health clients served Fee-for-Service and through contracted Medicaid Managed Care Organizations Updated January
More informationMedication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs
Medication Assisted Treatment Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Disclosures Employed by the Department of Veterans Affairs
More informationPOLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences POLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE MARK DUNCAN, MD November 8, 2018 SPEAKER
More informationMedication-Assisted Treatment (MAT) Overview
Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for
More informationOpioid Use and Justice Involvement: Challenges in Treatment, Engagement, and Continuity
Opioid Use and Justice Involvement: Challenges in Treatment, Engagement, and Continuity Holly Hills, Ph.D. June 13, 2017 Department of Mental Health Law and Policy Overview: Persons who have not been in
More informationManagement of high risk MMT patients. Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013
Management of high risk MMT patients Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013 CFPC CoI Templates: Slide 1 Faculty Disclosure Faculty: Meldon Kahan Relationships with commercial
More informationAGENDA U.S. SURGEON GENERAL, VIVEK MURTHY MD 2/5/2019
FORMER U.S. SURGEON GENERAL, VIVEK MURTHY MD AN ESTIMATED 20.8 MILLION PEOPLE IN OUR COUNTRY ARE LIVING WITH A SUBSTANCE USE DISORDER. THIS IS SIMILAR TO THE NUMBER OF PEOPLE WHO HAVE DIABETES, AND 1.5
More informationU.S. SURGEON GENERAL, VIVEK MURTHY MD
FORMER U.S. SURGEON GENERAL, VIVEK MURTHY MD AN ESTIMATED 20.8 MILLION PEOPLE IN OUR COUNTRY ARE LIVING WITH A SUBSTANCE USE DISORDER. THIS IS SIMILAR TO THE NUMBER OF PEOPLE WHO HAVE DIABETES, AND 1.5
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationDeveloped and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services
Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services www.randallwebber.com MAT clients are still addicted Truth: MAT clients will experience withdrawal symptoms if they stop
More informationPublic Health Association of British Columbia
October 30 th, 2017 Open Letter to the Government of British Columbia: BC Needs an OPIOID ACTION PLAN Since April, 2016 when the epidemic of opioid overdose deaths was declared a Public Health Emergency
More informationHARM REDUCTION & TREATMENT. Devin Reaves MSW
HARM REDUCTION & TREATMENT Devin Reaves MSW The mission of PAHRC is to promote the health, dignity, and human rights of individuals who use drugs and communities impacted by drug use. Recognizing that
More informationBuprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008
Buprenorphine: An Introduction Sharon Stancliff, MD Harm Reduction Coalition September 2008 Objective Participants will be able to: Discuss the role of opioid maintenance in reducing morbidity and mortality
More informationDisclosure Statement. Learning Objectives. American Psychiatric Nurses Association. Christian J. Teter, PharmD, BCPP 1 BUPRENORPHINE UPDATE
BUPRENORPHINE UPDATE Christian J. Teter, Pharm.D., BCPP Associate Professor, Psychopharmacology College Of Pharmacy, University Of New England Portland, ME E-Mail: cteter@une.edu Image Source: pubchem.ncbi.nlm.nih.gov
More informationNORTHWEST AIDS EDUCATION AND TRAINING CENTER. Opioid Use Disorders. Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Opioid Use Disorders Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014 Opioid Use Disorders Importance of opioid use disorders Screening and
More informationTreating Opioid Use Disorders: An Update for Counselors and Other Providers
Treating Opioid Use Disorders: An Update for Counselors and Other Providers Brad Shapiro, MD Medical Director Opiate Treatment Outpatient Program Zuckerberg San Francisco General THE DOSING WINDOW HISTORICAL
More informationPrescription Opioid Addiction
CSAM-SCAM Fundamentals Prescription Opioid Addiction Presentation provided by Meldon Kahan, MD Family & Community Medicine University of Toronto Conflict of interest statement I received funds from Rickett
More informationMAT 101: TREATMENT OF OPIOID USE DISORDER
MAT 101: TREATMENT OF OPIOID USE DISORDER WITH SPECIAL EMPHASIS ON BUPRENORPHINE/NALOXONE ICADD May 22, 2018 Alicia Carrasco, MD Debby Woodall, LCSW, ACADC Magni Hamso, MD, MPH Terry Reilly Health Services
More informationSubstance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates
Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral
More informationThe CARA & Buprenorphine Prescribing for APNs & PAs
The CARA & Buprenorphine Prescribing for APNs & PAs William J. Lorman, JD, PhD, MSN, PMHNP-BC, CARN-AP FIAAN Assistant Clinical Professor, Drexel University, Philadelphia, PA V. P. & Chief Clinical Officer,
More informationOpioid Treatment in North Carolina SEPTEMBER 13, 2016
Opioid Treatment in North Carolina SEPTEMBER 13, 2016 Source Where Pain Relievers Were Obtained for Most Recent Nonmedical Use among Past Year Users Aged 12 or Older: 2007 Source Where Respondent Obtained
More informationImplementing Buprenorphine Treatment in Opioid Treatment Programs Webinar 2, October 3, 2018
Implementing Buprenorphine Treatment in Opioid Treatment Programs Webinar 2, October 3, 2018 Judith Martin, MD, Medical Director of Substance Use Services, San Francisco Department of Public Health Webinar
More informationHarm Reduction in the Hospital: Preventing AMA Discharges and ED Bounce Backs
Harm Reduction in the Hospital: Preventing AMA Discharges and ED Bounce Backs Kathryn Dong MD, MSc, FRCP, DABAM Director, Inner City Health and Wellness Program, Royal Alexandra Hospital Associate Clinical
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) What has changed? Effective January 16, 2018, Coordinated Care will change the requirement for form HCA 13-333 Medication
More informationOpioid dependence and buprenorphine treatment
Opioid dependence and buprenorphine treatment David Roll, MD Revere Family Health, Cambridge Health Alliance Instructor in Medicine, Harvard Medical School Joji Suzuki MD Medical Director of Addictions
More informationLESSONS FROM THE PHYSICIAN HEALTH PROGRAM (PHP) EXPERIENCE FOR TODAY'S NATIONAL OPIOID EPIDEMIC
LESSONS FROM THE PHYSICIAN HEALTH PROGRAM (PHP) EXPERIENCE FOR TODAY'S NATIONAL OPIOID EPIDEMIC Robert L. DuPont, M.D. President, Institute for Behavior and Health, Inc. 2 nd Annual Symposium on Addiction
More informationOPIOID SUBSTITUTION THERAPY RISKS & BENEFITS
OPIOID SUBSTITUTION THERAPY RISKS & BENEFITS LEO O. LANOIE, MD, MPH, FCFP, CCSAM, ABAM, FISAM, MRO Dr. Leo Lanoie, 2017 DISCLAIMER In the past year I have accepted funds from Purdue for speaking OPIOID
More informationOpioids Research to Practice
Opioids Research to Practice CRIT/FIT 2016 April 2016 Daniel P. Alford, MD, MPH Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research and Education
More informationROSC & MAT II: Opioid Treatment Services
ROSC & MAT II: Opioid Treatment Services September 23, 2015 Stan DeKemper Executive Director Indiana Credentialing Association on Addiction and Drug Abuse 1 GOALS Review medication assisted recovery Identify
More informationMedication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc.
Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc. Elements Behavioral Health Diplomate, American Board of Addiction
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Drug Misuse: opiate detoxification of drug misusers in the community, hospital and prison. 1.1 Short title Drug misuse detoxification
More informationModels of good practice in drug treatment in Europe. Project group
Models of good practice in drug treatment in Europe ( moretreat 2006329 ) Project group Hamburg, London, Rome, Stockholm, Vienna, Warsaw, Zurich Project duration: 17 months from April 2006 August 2008
More informationNow available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet
Now available SUBOXONE Once-daily dosing1 12 mg and 16 mg tablets A maintenance dose of SUBOXONE 12-16 mg once daily is clinically effective for most patients*1 Effective maintenance dosing with SUBOXONE
More informationNURSING INTAKE. Provider Name: Provider Signature: Nursing Summary. Are you pregnant at this time?
NURSING INTAKE Provider Name: Provider Signature: Date: Nursing Summary Are you pregnant at this time? 3 = Don t know 4 = Tubal ligation 5 = Menopause 6 = History of hysterectomy 7 = Other: 8 = N/A patient
More information9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare
Buprenorphine Treatment (Suboxone) Selahattin Kurter, MD Spectrum Healthcare Board Certified in Psychiatry and Addiction Medicine Disclosures No financial reimbursement for this lecture Consultant for
More informationBUPRENORPHINE and Office-Based Treatment of Opioid Use Disorder
BUPRENORPHINE and Office-Based Treatment of Opioid Use Disorder Stephen A. Wyatt, DO Anthony Dekker, DO William Morrone, DO Funding for this initiative was made possible (in part) by Providers Clinical
More informationAddressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention
The Accountable Community for Health of King County Addressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention May 7, 2018 1 Opiate Treatment & Overdose Prevention Project Goal Immediate:
More informationMethadone and Naltrexone ER
Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither I nor my
More informationSubstance Abuse Suboxone Treatment
Substance Abuse Suboxone Treatment Program Waterbury Hospital Infectious Disease Clinic Richard Smith, LCSW Leonard Savage, Consumer Steven I. Aronin, MD FACP, Program Director Ryan White All Grantee Meeting
More informationMedications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?
Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Yngvild Olsen, MD, MPH Cecil County Board of Health Workgroup Meeting Elkton, MD October 8, 2013 Objectives
More informationIncrease in Opioid Related Deaths What the Data Can Tell us. Ontario Methadone Prescriber s Conference November 7, 2014 Tara Gomes
Increase in Opioid Related Deaths What the Data Can Tell us Ontario Methadone Prescriber s Conference November 7, 2014 Tara Gomes Objectives Prescription Opioid Misuse and Abuse: How did we get here? Opioid
More informationNURSING FOLLOW-UP: BUPRENORPHINE/NALOXONE BUPRENORPHINE/NALOXONE CLINIC VISITS
Provider Name: NURSING FOLLOW-UP: BUPRENORPHINE/NALOXONE Provider Signature: Date: BUPRENORPHINE/NALOXONE CLINIC VISITS Once stable, schedule clinic visits every 2 to 4 weeks, with refills that coincide
More informationLatest Research on Addiction and Treatment
Latest Research on Addiction and Treatment Joshua D Lee MD MSc joshua.lee@nyumc.org / @DrJoshuaDLee Associate Professor NYU School of Medicine, Department of Population Health Disclosures, LeeJD Grants:
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Drug Misuse: opiate detoxification of drug misusers in the community, hospital and prison. 1.1 Short title Drug misuse detoxification
More information